Reference : In vitro and in vivo evaluation of [I-123]-VEGF(165) as a potential tumor marker
Scientific journals : Article
Human health sciences : Radiology, nuclear medicine & imaging
In vitro and in vivo evaluation of [I-123]-VEGF(165) as a potential tumor marker
Cornelissen, B. [> > > >]
Oltenfreiter, R. [> > > >]
Kersemans, V. [> > > >]
Staelens, L. [> > > >]
Frankenne, Francis [ > > ]
Foidart, Jean-Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique >]
Slegers, G. [> > > >]
Nuclear Medicine & Biology
Pergamon Press
Yes (verified by ORBi)
United Kingdom
[en] cancer ; vascular endothelial growth factor ; molecular imaging receptor scintigraphy
[en] One of the research challenges in oncology is to develop new biochemical methods for noninvasive tumor therapy evaluation to determine,whether the chemotherapeutics is effective. Vascular endothelial growth factor (VEGF) was labeled with radioiodine and evaluated in vitro as well as in vivo, using A2058, a melanoma cell line overexpressing VEGFR-1 and -2. Saturation binding analysis with [I-125]-VEGF resulted in a K-d of 0.1 nM. Internalization assays indicate the preserved ligand induced internalization and metabolization of the tracer. Biodistribution studies with [I-123]-VEGF in wild type and A2058 tumor-bearing athymic mice showed low background activity and a tumor to reference tissue ratio of maximum 6.12. These results suggest that [I-123]-VEGF is a potentially suitable tracer for tumor therapy evaluation. (c) 2005 Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Open access
Cornelissen B NMB 2005.pdf1.pdfAuthor postprint278.12 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.